Si-BONE, Inc. is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation. These advances aim to streamline instrumentation, reduce surgical time and enhance early postoperative stability. Si-BONE’s development pipeline focuses on novel implant geometries and ancillary fixation solutions to broaden clinical indications and address adjacent biomechanical targets.
Headquartered in Santa Clara, California, Si-BONE markets its products through a dedicated direct sales organization in the United States and a network of distributors and strategic partners across Europe, Asia-Pacific and Latin America. The company supports a growing base of orthopedic and neurosurgeons through surgeon education programs, hands-on cadaver labs and a robust clinical registry that tracks real-world outcomes.
Founded in 2008, Si-BONE has built a compelling evidence package supported by peer-reviewed publications, prospective trials and retrospective analyses. Management continues to leverage its clinical research platform to validate the long-term safety and efficacy of its implants while exploring opportunities to expand its technology into complementary spinal indications.
